Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VBI Vaccines Inc.    VBIV   CA91822J1030

VBI VACCINES INC.

(VBIV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 0.49, which offers good timing for buyers.
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The company has insufficient levels of profitability.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's earnings releases usually do not meet expectations.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
VBI VACCINES INC.-31.16%169
LONZA GROUP8.10%30 492
IQVIA HOLDINGS INC.-30.19%21 784
CELLTRION, INC.1.65%20 184
SEATTLE GENETICS, INC.0.98%19 860
INCYTE CORPORATION-17.35%15 645
GALAPAGOS-2.95%12 475
ALNYLAM PHARMACEUTICALS, IN..-5.49%12 306
MODERNA, INC.53.12%11 236
QIAGEN N.V.23.08%9 212
ICON PUBLIC LIMITED COMPANY-21.04%7 537
BIO-TECHNE CORPORATION-13.62%7 317
HANGZHOU TIGERMED CONSULTIN..-4.96%6 713
IONIS PHARMACEUTICALS, INC.-21.73%6 712
CHARLES RIVER LABORATORIES ..-17.38%6 433
ACADIA PHARMACEUTICALS INC.-1.24%6 419
More Results
Financials (USD)
Sales 2020 3,38 M
EBIT 2020 -47,6 M
Net income 2020 -49,4 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -3,61x
P/E ratio 2021 -4,19x
Capi. / Sales2020 50,1x
Capi. / Sales2021 34,7x
Capitalization 169 M
Upcoming event on VBI VACCINES INC.
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes